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Abstract
Circulating full-length and caspase-cleaved cytokeratin 18 (CK18) are considered biomarkers of chemotherapy-
induced cell death measured using a combination of the M30 and M65 ELISAs. M30 measures caspase-cleaved
CK18 produced during apoptosis and M65 measures the levels of both caspase-cleaved and intact CK18, the latter
of which is released from cells undergoing necrosis. Previous studies have highlighted their potential as prognos-
tic, predictive, and pharmacological tools in the treatment of cancer. Disseminated testicular germ cell cancer (TC)
is a paradigm for a chemosensitive solid malignancy of epithelial origin and has a cure rate of 80% to 90%. We
conducted M30/M65 analyses on 34 patients with TC before and during treatment with bleomycin, etoposide, and
cisplatin and showed that prechemotherapy serum levels of M65 and M30 antigens are correlated with estab-
lished TC tumor markers lactate dehydrogenase, α-fetoprotein, and β-human chorionic gonadotropin, probably re-
flecting tumor load. Cumulative percentage change of M65 and M30 from baseline to end of study was highest in
poor prognosis patients (P < .05). Moreover, area under the curve profiles of M65 and M30 during chemotherapy
mirrored dynamic profiles for lactate dehydrogenase, α-fetoprotein, and β-human chorionic gonadotropin. Con-
sequently, M65 and M30 levels appear to reflect chemotherapy-induced changes that correlate with changes in
markers routinely used in the clinic for management of patients with TC. This is the first clinical study where M65
and M30 antigen levels correlate with established prognostic markers and provides impetus for their exploration in
other epithelial cancers where there is a pressing need for informative circulating biomarkers.
Neoplasia (2008) 10, 1041–1048
Introduction
The development of novel, targeted anticancer therapies coupled with
an increased understanding of the molecular processes that occur
during cancer progression bring with them an ever more pressing need
for the development of clinically robust biomarkers [1,2]. Ideally,
these assays may provide information such as optimal patient selection
for the design of clinical trials as well as enable real-time evaluation
of treatment efficacy and/or toxicity [3,4]. These biomarkers may also
facilitate no-go/go decision making that is so crucial during the drug
discovery process [5].
Abbreviations: αFP, α-fetoprotein; AUC, area under the curve; BEP, bleomycin, etoposide
and cisplatin; βHCG, β-human chorionic, gonadotropin; ChC, choriocarcinoma; CK18,
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The M30- and M65-based sandwich ELISAs determine the circu-
lating levels of different forms of the protein cytokeratin 18 (CK18)
and are proposed as surrogate biomarkers of drug-induced cancer cell
death [6–8]. Cancers of epithelial origin are known to contain rela-
tively large intracellular pools of soluble and insoluble cytokeratins.
However, during necrotic and apoptotic cell death, CK18 and other
cytokeratins are released into the blood in either their intact or their
caspase-cleaved forms where they remain relatively stable in the cir-
culation of patients with cancer [9].
The M30 detection antibody recognizes a neo-epitope mapped to
positions 387 to 396 of CK18, so called CK18-Asp396, that is only
revealed after caspase cleavage of the protein and is postulated as a
selective biomarker of apoptosis [10]. The M65 ELISA detects a
common epitope present in the full-length protein as well as in the
caspase-cleaved fragment [8] and is thus believed to measure, in ad-
dition to apoptosis, intact CK18 that is released from cells under-
going necrosis [11]. Both assays have now been validated as “fit for
purpose” in the analysis of plasma and serum collected from subjects
entered into clinical trials [12–15] and have been extensively applied
as pharmacodynamic biomarkers of chemotherapy-induced cell death
in a range of different cancer types treated with different chemothera-
peutic agents [6,8,16–19].
Testicular germ cell cancer (TC) is the most common malignancy
in men between 20 and 35 years old. At the time of diagnosis, up to
50% of patients with TC have disseminated disease and the current
standard chemotherapy regimen consists of treatment with a combi-
nation of bleomycin, etoposide, and cisplatin (BEP). TC can be con-
sidered a paradigm for a chemosensitive solid tumor, as the cure rate
for disseminated TC is high (80% to 90%), although about 20% to
30% of the patients diagnosed with disseminated disease will dis-
play intrinsic resistance or will acquire resistance to first-line chemo-
therapy and about 10% will eventually die from TC.
Approximately 90% of the patients with disseminated TC have
elevated levels of one or more of the following serum tumor markers:
lactate dehydrogenase (LDH), α-fetoprotein (αFP), and β-human
chorionic gonadotropin (βHCG). Normalization of these tumor
markers is the most commonly used criterion for favorable tumor
response [20] and levels usually decrease within 5 to 12 days after
the start of chemotherapy [21]. When marker levels normalize dur-
ing or after completion of chemotherapy, patients are considered to
have had a complete biochemical tumor response. In the cases where
residual disease is present, it will be treated surgically [22,23]. Upon
complete remission, regular measurement of serum tumor markers is
an essential component of the follow-up of patients with TC [24,25].
In addition, LDH, αFP, and βHCG are used, in combination with
the localization of the primary tumor and the presence of nonpul-
monary visceral metastases, for prognosis estimation according to
the International Germ Cell Consensus Classification (IGCCC). Ini-
tial increase in αFP levels after start of chemotherapy appears to be
associated with unfavorable outcome [26].
It must be noted, however, that initial levels of these serum tumor
markers have a limited predictive value for disease outcome in the in-
dividual patient. Moreover, up to 10% of patients with disseminated
TC do not have elevated tumor markers. Thus, additional serological
biomarkers may contribute to a better prediction of response to che-
motherapy and disease outcome.
We have conducted an exploratory study where we have investi-
gated changes in serum and plasma concentrations of total CK18
(M65 antigen) and caspase-cleaved CK18 (M30 antigen) in patients
with TC before and serially after treatment with BEP chemotherapy
and their association with changes in the clinically used tumor mar-
kers LDH, αFP, and βHCG and treatment outcome.
Patients and Methods
Patients and Collection of Blood Samples for Analysis
of CK18 and Caspase-Cleaved CK18
Blood samples were collected from two groups of patients and an-
alyzed for the acute effects of chemotherapy for disseminated TC. All
patients received BEP chemotherapy, consisting of a combination of
bleomycin (30 mg on days 2, 8, and 15 of each course), etoposide
(100 mg/m2 on days 1 to 5), and cisplatin (20 mg/m2 on days 1 to 5)
for three or four courses of 3 weeks.
We collected blood samples of 11 consecutive patients with TC
participating in a prospective study on acute effects of BEP chemo-
therapy and treated from May 2006 to November 2006. For this
study, both serum and heparin plasma were collected on day 1 (be-
fore start of chemotherapy) and heparin plasma for days 2 (24 hours
after start), 3 (48 hours after start), 6, 8, and 15 of the first course
and days 1, 8, and 15 of the following courses. Samples were stored
at −20°C.
To extend our exploratory analysis, we selected from our serum
bank a group of 23 patients with TC treated with BEP chemotherapy
at the University Medical Center Groningen, the Netherlands, be-
tween January 2004 and May 2006. Selection was based on the avail-
ability of serum samples and diversity with respect to the histologic
composition of the primary tumor, IGCCC prognosis group, disease
outcome, and levels of tumor markers LDH, αFP, and βHCG. From
the stored serum samples (at −20°C) we selected samples from before
the start of chemotherapy and days 1, 8, and 15 of each chemother-
apy course. If no samples were available for days 1, 8, or 15, a sample
from 1 day before or after was analyzed.
The analysis of blood samples was approved by the local medical
ethical committee and written informed consent was obtained from
each participant.
Immunochemistry for CK18 and Caspase-Cleaved CK18
in Tumor Material
Paraffin-embedded testicular tumor material was collected for each
patient before the start of chemotherapy and analyzed for CK18 and
caspase-cleaved CK18. For immunohistochemistry, 3-μm sections
were cut and placed on 3-Aminopropyltriethoxysilane-coated slides,
deparaffinized and dehydrated. The presence of testicular germ cell
tumor components was confirmed by a pathologist using standard
hematoxylin-eosin staining. For staining of CK18, endogenous per-
oxidase was blocked (30 minutes, 0.3% H2O2); in addition, sections
were pretreated with 0.1% protease XXIV for 30 minutes (Sigma-
Aldrich, St. Louis, MO) followed by incubation with avidin and,
subsequently, biotin blocking solution, both for 15 minutes (Vector
Laboratories, Burlingame, CA). For staining of caspase-cleaved CK18,
sections were preheated by microwave for 8 minutes at 700 W in
citrate buffer (0.1 M, pH 6.0) followed by blocking of endogenous
peroxidase activity as described above.
Subsequently, slides were incubated for 1 hour with the primary
antibody: CAM5.2 (Becton-Dickinson, San Jose, CA) recognizing
both CK18 and CK8, which show a similar tissue distribution, or
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M30 antibody (Boehringer Mannheim GmbH, Mannheim, Ger-
many) to detect CK18-Asp396. A secondary biotinylated rabbit anti–
mouse antibody followed by a tertiary StreptAB-complex/HRP
and peroxidase-conjugated rabbit anti–mouse antibody followed by
peroxidase-conjugated goat anti–rabbit antibody (antibodies from
DAKO, Glostrup, Denmark) were used, respectively. DAB was used
as chromagen to visualize peroxidase activity. Counterstaining was
performed with hematoxylin. Immunoglobulin class-matched control
sera were used as negative controls. Normal appendix tissue served as a
positive control for CK18 and CK8, and colon carcinoma tissue for
caspase-cleaved CK18.
Measurement of CK18 and Caspase-Cleaved CK18
in Tumor Material by Immunohistochemistry
Evaluation of staining was performed by a pathologist without
knowledge of the clinical data. With respect to CK18/CK8 (recog-
nized by CAM5.2), tumor components showing no positive cells
were considered negative (−), whereas tumor components showing
stained tumor cells were considered positive (± in the presence of
focal positive staining or + in the presence of diffuse positive stain-
ing). For caspase-cleaved CK18, tumor components showing positiv-
ity in less than five high-power fields (with a field diameter of 0.55 mm)
were considered negative (−). Focal positivity for caspase-cleaved
CK18 was scored +, whereas the presence of massive positivity was
scored ++. Heterogeneity and pattern of staining regarding each
tumor component were also recorded.
Determination of CK18 (M65 ELISA) and Caspase-Cleaved
CK18 (M30 ELISA) in Blood
The M30 apoptosense and M65 ELISA kits were both obtained
from PEVIVA AB (Bromma, Sweden), and these assays, previously
validated for clinical trial use, were performed under dedicated Good
Clinical Laboratory Practice conditions as previously described [12–
14]. Background variation for M65 and M30 antigens is considered
as ±30% of the antigen level seen at the start of each treatment cycle
as discussed previously [13]. Any peaks or troughs seen in patient anti-
gen levels falling outside this range may be considered a direct result of
chemotherapy: either tumor response or toxicity.
Statistics
Data were analyzed statistically with SPSS software package (SPSS
Inc., Chicago, IL). Groups were compared for M65 and M30 by
using the Mann-Whitney U test, whereas changes in M65 and
M30 over time were tested with the paired Wilcoxon signed rank test.
The Kruskal-Wallis nonparametric test was performed to test for sig-
nificant differences among the distributions of the three prognosis
groups. Post hoc pairwise comparisons were made with Bonferonni
correction when appropriate.
To calculate the cumulative percentage change in M65 and M30
levels over the entire treatment period, values with a 30% threshold
from the predose value for each chemotherapy course were judged to
be either a “peak” (increase above threshold), a “trough” (decrease
below threshold), or “no change” (remaining either above, below,
or within the 30% threshold in line with the previous reading)
[13]. At each peak and trough, the absolute values of M30 and
M65 were recorded and summed over the entire treatment period
to give the cumulative percentage change.
To calculate the area under the curve (AUC) values from the mea-
sured concentrations at sequential, specific sampling points, the trape-







where cn and tn are the concentration and time point, respectively,
for the nth time point. To determine the extent to which the AUC
values of M65, M30, and the standard tumor markers LDH, αFP,
and βHCG are proportional to each other, weekly AUC data for all
five markers were normalized between 0 and 1 using minmax nor-
malization [27] so that a direct comparison could be made between
these markers in terms of the AUC profile over the entire period.




General patient characteristics are summarized in Table 1. Among the
total group of 34 patients there were 4 patients with refractory disease.
CK18 and Caspase-Cleaved CK18 (M30) in Primary
Tumor Material
For each patient, every testicular germ cell tumor component was
scored separately for the expression of CK18/CK8 and caspase-
cleaved CK18. All nonseminomatous histologic components were
positive for CK18/CK8 (all +), with the embryonal carcinoma
(EC) component showing most positivity (Figure 1A), followed by
the choriocarcinoma (ChC) component. These two components were
also most often positive for caspase-cleaved CK18 (EC, 22/22 ++;
ChC, 1/6 + and 5/6 ++), with the variable presence of so-called apo-
necrosis in EC components. Noteworthy, the yolk sac tumor (YS)
component was negative for caspase-cleaved CK18 when it had the
Table 1. General Patient Characteristics.
Prospective Group Serum Bank Group
No. of patients 11 23
Age, median (range) (years) 35 (19–46) 31 (19–53)
Histology, N (%)
Nonseminoma 10 (91) 21 (91)
Seminoma 1 (9) 2 (9)
Stage, N (%)*
II 9 (82) 15 (65)
III 1 (9) 1 (4)
IV 1 (9) 7 (31)
Prognosis group, N (%)†
Good 10 (91) 11 (48)
Intermediate 1 (9) 7 (30)
Poor 0 (0) 5 (22)
Chemotherapy regimen, N (%)
4 BEP 2 (18) 20 (87)
3 BEP 9 (82) 3 (13)
Response to chemotherapy, N (%)
Complete biochemical response 4 (36) 7 (30)
Complete biochemical response + surgery 6 (55) 13 (57)
Teratoma 4 8
Necrosis 2 5
Refractory disease 1 (9) 3 (13)
*Royal Marsden classification.
†IGCC classification.
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reticular pattern, whereas it showed positivity for caspase-cleaved
CK18 with aponecrosis in the solid pattern, which is histologically
more similar to the EC pattern (YS, 3/6 −, 2/6 +, and 1/6 ++). Mature
teratoma (MT) and immature teratoma (IT) components showed
variable expression of caspase-cleaved CK18 (MT, 11/12 − and 1/12 +;
IT, 3/5 − and 2/5 +) (Figure 1B).
The seminoma (S) component was negative for both CK18/CK8
(7/8 − and 1/8 ±) and caspase-cleaved CK18 (8/8 −; Figure 1C ) with
the exception of one patient who had a mixed germ cell tumor with
focal positivity for CK18/CK8 in the S component.
Circulating CK18 (M65) and Caspase-Cleaved CK18 (M30)
before Chemotherapy
Prechemotherapy sera were taken and analyzed for M65 and M30
antigen levels from 23 retrospectively sampled patients; data were
grouped according to IGCCC prognosis group guidelines (good, in-
termediate, or poor). Serum levels of M65 and M30 antigens varied
significantly according to prognosis group (Figure 2A). Patients in
the poor-prognosis group showed the highest median level of M65
(2456 U/l) followed by the intermediate-prognosis group (642 U/l)
and then the good-prognosis group (366 U/l). Median M30 levels fol-
low the same pattern (poor-prognosis group, 648 U/l; intermediate-
prognosis group, 219 U/l; and good-prognosis group, 144 U/l).
Changes in Circulating CK18 (M65) and Caspase-Cleaved
CK18 (M30) during the First Chemotherapy Course
For the 11 patients participating in the prospective study, data were
available at early time points at 24 hours, 48 hours, 5 days, 7 days,
14 days, and 21 days after start of chemotherapy (first chemotherapy
course) (Figure 3). Up to 7 days after start of chemotherapy there was a
significant increase in median M65 level (prechemotherapy, 384 U/l,
after 7 days 483 U/l; P = .010) and median M30 level (prechemo-
therapy, 267 U/l; after 7 days, 338 U/l; P = .026). This peak was fol-
lowed by a significant decrease in M65 levels compared to baseline
values resulting in a median level of 294 U/l at 14 days (P = .021)
and 307 U/l (P = .016) at 21 days after start of chemotherapy.
M30 levels were also decreased compared to prechemotherapy levels
14 days after start of treatment (median, 203 U/l; P = .008).
Circulating CK18 (M65) and Caspase-Cleaved CK18 (M30)
Profiles in Patients from the Three IGCCC Prognosis Groups
Typical examples of individual patient profiles from each of the
three groups are shown in Figure 4. Arrows indicate the start of each
Figure 1. Expression of CK18/CK8 (CAM5.2) and caspase-cleaved
CK18 (M30) in different testicular germ cell tumor components. (A)
Embryonal carcinoma (EC): positive for CK18/CK8 and apoptotic
cells are positive for caspase-cleaved CK18. (B) Mature teratoma
(MT): in general positive for CK18/CK8 and negative for caspase-
cleaved CK18. (C) Seminoma (S): negative for both CK18/CK8 and
caspase-cleaved CK18.
Figure 2. (A) Prechemotherapy serum levels of total CK18 (M65)
and caspase-cleaved CK18 (M30) according to prognosis group
(IGCCC) in all groups of analyzed patients (n = 34). (B) Cumu-
lative percentage changes in total CK18 (M65) and caspase-
cleaved CK18 (M30) levels over entire treatment period grouped
by IGCCC prognosis for samples collected from serum bank
(n = 23). *Significant difference from good-prognosis group
(P < .05). **Significant difference from good and intermediate-
prognosis group (P < .05).
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cycle of chemotherapy and error bars at each of these points indicate
the 30% signal-to-noise ratio; thus, values outside this range are
considered significant [13]. Patients in the good and intermediate-
prognosis group (Figure 4, A and B, respectively) displayed repeated
drug-induced spikes in M30 and M65 levels throughout the course
of therapy, whereas M65 and M30 antigen levels for the patients in
the poor-prognosis group were initially very high and declined rap-
idly on the first chemotherapy course with the absence of clear peaks
(Figure 4C ). The four patients with refractory disease showed a pro-
file similar to that of the 30 patients with a favorable tumor response.
Cumulative Changes in Circulating CK18 (M65)
and Caspase-Cleaved CK18 (M30) over the Entire
Treatment Period
Changes in circulating M65 and M30 were analyzed in the
23 patients for whom samples were available throughout their en-
tire treatment regime. Cumulative percentage changes in M65 (good
prognosis, 166.5%; intermediate prognosis, 121.3%; and poor prog-
nosis, −119.4%) and M30 (good prognosis, 90.4%; intermediate
prognosis, 69.7%; and poor prognosis, 25.5%) over the entire treat-
ment period differed highly according to IGCCC prognosis group.
Patients in the poor-prognosis group showed the largest cumulative
decrease in both M65 and M30 (Figure 2B). The median cumulative
change in M65 in the poor-prognosis group differed significantly from
the good-prognosis group (P = .002) and intermediate-prognosis
group (P = .008), whereas the median cumulative changes in M30
also differed between the poor-prognosis patients and good-prognosis
patients (P = .011), but not between the poor- and intermediate-
prognosis patients.
Correlation between Circulating CK18 (M65),
Caspase-Cleaved CK18 (M30), and Standard
Tumor Markers
Prechemotherapy serum levels of M65 and M30 were strongly
positively correlated with circulating levels of the standard TC tumor
markers LDH, βHCG and αFP (Table 2).
AUC analysis of median week-by-week changes in M65 (Fig-
ure 5A) showed a significant difference according to IGCCC prog-
nosis group during the first 2 weeks of chemotherapy (P < .05) and
was able to distinguish patients in the poor-prognosis group during
subsequent rounds of treatment (P < .05). Similarly, M30 levels
showed significant variation according to prognosis group during
the first 2 weeks of treatment (P < .05) (Figure 5B). Of particular
Figure 3. Changes in circulating CK18 (M65) and caspase-cleaved
CK18 (M30) in serum of patients with TC (n = 11) during the first
course of BEP chemotherapy. The median values are connected by
a line. *Median level significant different from baseline (P < .05).
Figure 4.M30 and M65 profiles in a patient from the three IGCCC-
defined prognosis groups: (A) good prognosis, (B) intermediate
prognosis, (C) poor prognosis. Serum from patients receiving stan-
dard chemotherapy for TC was analyzed for circulating CK18
(M65) and caspase-cleaved CK18 (M30). Arrows indicate the start
of each chemotherapy course and error bars indicate 30% signal-
to-noise ratio for each treatment cycle.
Table 2. Correlation between Circulating CK18 (M65), Caspase-Cleaved CK18 (M30) in Serum,
and Standard Tumor Markers Before Start of Chemotherapy.
Tumor Marker Correlation Coefficient (Spearman’s Bivariate Correlation Test)
M65 P M30 P
LDH (n = 34) 0.698 0.000 0.586 0.000
αFP (n = 20)* 0.129 0.588 0.475 0.034
βHCG (n = 22)* 0.866 0.000 0.864 0.000
Values in bold indicate significance (P < .05).
*Analysis includes patients in whom concerned tumor marker was elevated before start of chemotherapy.
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note is the finding that AUC analyses of M65 and M30 levels during
chemotherapy exhibited profiles that were remarkably similar to
those of the standard tumor markers (Figure 5C ). Spearman’s corre-
lation analysis showed a significant correlation between both M65
and M30 with LDH in all three prognosis groups, βHCG in inter-
mediate and poor-prognosis groups, and αFP in the poor-prognosis
group (P < .05; Table 3).
Discussion
The high levels of intact and caspase-3 cleaved CK18 in the cir-
culation of patients with epithelial malignancies have been attributed
to intracellular proteins that have been shed into the blood from
dying tumor cells [16,18,19]. Similarly, increases in circulating levels
of CK18 after chemotherapy have also been reported, and thus this
protein is considered to be a serological biomarker of tumor cell
death [16,19,28].
The expression of CK18 in nonseminomatous histologic compo-
nents of TC renders CK18 and its caspase-cleaved fragment CK18-
Asp396 candidate biomarkers for chemotherapy-induced tumor cell
death and cell death mode (apoptosis vs. necrosis) in nonseminomatous
patients with TC. This exploratory study shows that serum levels of
CK18 (M65 antigen) and caspase-cleaved CK18 (M30 antigen) before
chemotherapy are associated with prognosis group according to
IGCCC classification and are correlated with prechemotherapy levels
of tumor markers LDH, αFP, and βHCG. In addition, changes in
M65 and M30 are observed during chemotherapy. These changes con-
sist of an overall decrease combined with peaks during most chemother-
apy courses in the good and intermediate-prognosis group. AUC
analysis shows that changes in M65 and M30 are strongly correlated
with chemotherapy-induced changes in LDH, αFP, and βHCG.
In our patients, CK18 and caspase-cleaved CK18 levels also vary
with different histologic components of germ cell tumors [29,30]. It
seems conceivable that the large variation in blood levels of M65 and
M30 before chemotherapy is partially caused by the present tumor
mass or masses, their histologic composition, and the baseline levels
of spontaneous tumor cell death. Moreover, the observed association
with IGCCC prognosis group and tumor markers LDH, βHCG,
and αFP suggests that the height of M65 and M30 levels is primarily
influenced by tumor load.
Because CK18-Asp396 is expressed during apoptosis and released
during loss of cell membrane integrity with further progression of
apoptosis or secondary necrosis, we prospectively analyzed changes
in serum M65 and M30 in 11 patients with TC shortly after start
of chemotherapy. An increase in M65 and M30 levels was observed
Figure 5. AUC data for (A) circulating CK18 (M65) and (B) caspase-
cleaved CK18 (M30) according to IGCCC prognosis group. (C)
Levels of M65, M30, and standard tumor markers LDH, αFP,
and βHCG combined as normalized AUC data. The arrows indicate
the start of each chemotherapy course.
Table 3. Correlation between Serum Levels of CK18 (M65), Caspase-Cleaved CK18 (M30) in
Serum, and Standard Tumor Markers during Chemotherapy, Using Weekly AUC Data.
Prognosis Group Correlation Coefficient (Spearman’s Bivariate Correlation Test)
Tumor Marker M65 M30
Good (n = 11) LDH (n = 11) 0.804 0.593
αFP (n = 5)* −0.262 0.182
βHCG (n = 8)* −0.295 0.092
Intermediate (n = 7) LDH (n = 7) 0.654 0.579
αFP (n = 4)* 0.546 0.547
βHCG (n = 5)* 0.561 0.579
Poor (n = 5) LDH (n = 5) 0.980 0.967
αFP (n = 4)* 0.975 0.963
βHCG (n = 5)* 0.963 0.973
Values in bold indicate significance (P < .05). Samples were taken from the retrospective study (n = 23).
*Analysis includes patients in whom concerned tumor marker was elevated before start of chemotherapy.
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up to 7 days after start of the chemotherapy. In previous studies on
the effects of chemotherapy in patients with breast cancer and pros-
tate cancer, increases in M65 and M30 levels were found within 1 to
3 days after start of chemotherapy [17,31]. We observed most signif-
icant changes 7 days after start of treatment, which may reflect the
cumulative effect of the 5-day dosing scheme of cisplatin and etopo-
side during BEP chemotherapy.
During the following courses, an overall decrease is observed with
the superposition of peaks for both M65 and M30 after start of a
new chemotherapy course in good- and intermediate-prognosis pa-
tients. Poor-prognosis patients show the most pronounced overall
decrease in M65 and M30. The profiles and AUC change of M65
and M30 appear to mirror the profiles of the standard tumor mark-
ers both before the start of chemotherapy and throughout treat-
ment. This strong correlation suggests that the overall decrease in
M65 and M30 are indicative of treatment response, as they appear
to reflect a decrease in tumor load due to chemotherapy-induced
tumor cell death. A comparable association has been found between
docetaxel-induced increases of M30 and baseline levels of PSA, re-
flecting tumor volume in patients with prostate cancer [17]. In ad-
dition, serum M30 levels in patients with breast cancer correlated
with the number of involved organs [18].
In addition, the peaks of M65 and M30 observed after the start of
each treatment cycle in good and intermediate-prognosis group pa-
tients indicate a drug-induced effect, which may reflect tumor re-
sponse. The fact that these peaks are not observed in patients with
poor prognosis is possibly related to high initial levels of M65 and
M30. With this exploratory analysis in a small number of selected
patients, it cannot be proven that M65 and M30 peaks are specific
enough for chemotherapy-induced tumor cell death. Neither can it
be excluded that these peaks (partially) reflect chemotherapy-induced
toxicity to normal epithelial tissue. Recently, elevated serum levels of
caspase-cleaved CK18 have been found in, for instance, patients with
an acute myocardial infarction [32].
The four patients with TC who eventually did not respond to BEP
chemotherapy after an initial decline in tumor markers showed pat-
terns of M30 and M65 comparable to responding patients, including
chemotherapy-induced peaks. In case these peaks are tumor cell death
related, they may represent cell death of chemotherapy-sensitive sub-
populations of cells, reflected by initial decrease of tumor markers.
However, the number of refractory patients in this study is too small
to draw firm conclusions. Consequently, the presence of chemotherapy-
induced peaks in M65 and M30 may not exclude future treatment
failure. Correspondingly, increases in CK18 have been observed in
breast cancer patients with stable disease instead of clinical response
to chemotherapy [31].
With regard to the treatment of disseminated TC, the question re-
mains whether determination of M65 and M30 has additional value
for monitoring tumor response to chemotherapy. These results suggest
that M30 and M65 may reflect drug-induced changes in tumor; how-
ever, to have a predictive value for the individual patient, serum M65
and M30 need to show distinct patterns for patients with a favorable
disease outcome and for those with a nonfavorable disease outcome.
Fortunately, because the cure rate is so high for disseminated TC
(80% to 90%) a larger study containing more nonresponding patients
is needed to assess whether changes in M65 and M30 are specific
enough for tumor cell response and whether prechemotherapy levels
and early changes in M65 and M30 are predictive for disease outcome
in testicular cancer patients treated with chemotherapy.
This study is the first example in a clinical setting where circulat-
ing levels of M30 and M65 antigen correlate with internationally rec-
ognized circulating biomarkers that are routinely and successfully
used as prognostic indicators and for monitoring treatment response
in TC. The correlation between M65/M30 levels and IGCCC prog-
nosis group and their overall agreement with LDH, αFP, and βHCG
levels suggest that M65/M30 may also have a prognostic value in
patients with TC. This concordance of M30 and M65 with these
prognostic markers of TC adds to the momentum for future explo-
ration of M30 and M65 in other epithelial cancers where informative
circulating biomarkers are needed [16,17,19,31].
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